Visitors Now:
Total Visits:
Total Stories:
Profile image
By The Cato Institute Event Videos
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

The TPP and Pharmaceutical Protections: Too Strong, Too Weak, or Just Right?

Sunday, October 30, 2016 15:50
% of readers think this story is Fact. Add your two cents.

(Before It's News)

If enacted, the Trans-Pacific Partnership will promote economic growth in the United States and 11 other countries in the Asia-Pacific region by reducing protectionist trade barriers. The agreement will also set rules in areas other than trade policy, including minimum standards of patent protection in all member countries. These patent rules have led many groups to criticize the TPP and other similar agreements for increasing the cost of drugs in poor countries. Some proponents of the agreement counter by noting the importance of patent protection both for promoting the development of new drugs and for driving growth in high-tech industries. The most controversial pharmaceutical provision in the TPP has been a requirement to provide a greater period of exclusivity to a special class of drugs known as biologics. The U.S. pharmaceutical industry has complained that the TPP’s biologic provision is not strict enough, and powerful members of Congress may prevent the TPP’s ratification unless something can be done to strengthen the rule. Are the TPP’s patent rules too strong, too weak, or just right? Come hear our expert panel discuss what the TPP will do, or should do, to shape the global pharmaceutical market.

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.